hVIVO signs £11.5M RSV trial contract; expands services at new facility

(6:12)

Q\u0026A with hVIVO CEO, Mo Khan

(6:32)

Hvivo Q\u0026A: “this contract is important as it opens up new markets”

(10:19)

hVIVO secures record £2.7M laboratory services contract, expanding global impact in virology

(4:41)

hVIVO £14.7m Challenge virus manufacturing contract for top 5 global pharmaceutical client

(6:4)

hVIVO contract the fruit of increasing Asian focus

(3:56)

Alex Mann discusses hVIVO's new Influenza contract - BRR Media

(4:30)

CEO Yamin 'Mo' Khan on £5m RSV Challenge Study Contract

(3:45)

What Is Consulting? A Healthcare Consultant Perspective

(8:8)

Open Orphan PLC on hVIVO signing its first phase 2 field study contract

(5:55)

hVIVO Group 2024 Year in Review

(3:36)

hVIVO CEO reports on \

(6:52)

Mo Khan CEO of hVIVO, 2022 in Review

(12:5)

hVIVO CEO discusses record H1 revenue and strategic expansion

(8:17)

Q\u0026A with hVIVO’s Mo Khan

(8:3)

How To Use EndNote (A Complete Beginner's Guide)

(14:19)

Open Orphan announce Yamin 'Mo' Khan as new CEO

(5:32)

Open Orphan's chief financial officer confident of \

(4:45)

hLAB multi-site Phase 2 Field Trial Study and Capabilities

(3:11)

hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal

(4:50)

hVIVO Contract Win \u0026 Trading Update

(2:9)

hVIVO Year in Review 2024

(3:44)

hVIVO Asian growth strategy bearing fruit with second 2023 contract win

(4:7)

hVIVO signs second bespoke human challenge model contract in as many months

(5:45)

hVIVO's £7.2m RSV Human Challenge Model Contract

(4:7)

Associate Medical Director Role at hVIVO

(2:55)

Chief Scientific Officer on Human Challenge Trials \u0026 Canary Wharf State-of-the-Art facility

(3:38)

FluCamp Clinical Trials by hVIVO

(1:7)

hVIVO secures £2.5mln contract for Omicron characterisation study

(7:38)